As to PD-1 and possibly to TIGIT, and we have the ability to do the biomarker work, as I stated before that. And in general, there is interest in what PVRIG is generating. That’s on one hand. And our intention with this new study is to add additional — to add to the size that we have, as I said in the prepared remarks, to strengthen the evidence in order to able to understand the path forward in a better way and to also solidify this difference that we’re getting in tumor types that are hard to treat and mainly the PD-L1 low pace that is of high interest in the industry. We’re differentiating ourselves not only on the PVRIG asset, but also on the fact that we are targeting this PD-L1 low expression tumor types. So that’s in general. So one, I’m not commenting on specific discussions, that’s the general perspective.
Daina Graybosch: Thank you. My second question is on the concept study. I think you said for both MSS-CRC and platinum-resistant ovarian, that you’re enrolling patients with up to three prior lines. Does that mean these could be treatment-naive patients? How early do you expect to be able to enroll patients on these studies? And can you remind us how many lines on average in the range and the tax — and the data you could get in last year you had, how different are these new studies in terms of line from the last enrollment?
Anat Cohen-Dayag: Henry?
Henry Adewoye: Yes. So let’s stick with the ovarian cancer question first, Daina. So for ovarian cancer, what we are referring to or what Anat just mentioned in her prepared comments, is for the number of up to prior lines in platinum -resistant setting. So we’re not considering patient who’ve had platinum sensitive disease, in which case, they might have received platinum a number of times. So it is strictly for the platinum-resistant setting, okay, where the standard of care is chemotherapy for now, and I know, yes, we have a study drug that’s been conditionally approved or accelerated approval on EDC. Yes. So that’s — that’s what we mean by up to three prior lines. And then for colorectal cancer also, this is not in the earlier setting. This is in patients who have been exposed to standard of care therapy, most have received all the standard of care therapies include FOLFOX and FOLFIRI and more than three prior lines also for those patients.
Daina Graybosch: Great. Thank you.
Operator: The next question is from Tony Butler of EF Hutton. Please go ahead.
Charles Butler: This is Charles on for Tony. The trial as it appears on ClinicalTrials.gov today, at least there are six trial sites. I wonder if you could tell me how many of these trial sites are enrolling patients for the colorectal cancer arm? And then whether you intend to have more — have more trial sites enrolling more patients?
Anat Cohen-Dayag: Henry?
Henry Adewoye: So what we have on ClinicalTrials.gov is current. All the sites that we have listed for the dual combination study and for all the other studies that we have currently enrolling, open to enrollment for the colorectal cancer cohort. We expect that just based on the number of patients who have this unfortunate illness that enrollment should be brisk and will be on track, just like Anat mentioned.
Charles Butler: Yes, yes. Thank you for that. And what about ovarian cancer patients? Will that cohort be listed as a separate under this same trial? And the same question about trials sites?
